Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

If E.U. and U.S. negotiators make use of the delay to negotiate a deal that will lower or remove tariffs entirely, that would be even better news for Novo Nordisk stock -- and it's probably what ...

The new deal ... Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's Zepbound would no longer be preferred. Novo Nordisk ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Reuters reports that online weight loss company Noom will sell low-dose versions of Novo Nordisk's Wegovy. Compounding pharmacies like Noom have struggled to figure out how to sell GLP-1 weight ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

Novo Nordisk is banking on fresh leadership ... The company last week announced a licensing deal with the U.S. biotech company Septerna for experimental small-molecule pills for obesity and ...